Brainstorm Cell Therapeutics Inc. Stock News

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA… Read more

Brainstorm Cell Therapeutics (BCLI) said the Brazilian Patent Office granted a patent covering a method of manufacturing MSC-NTF cells (NurOwn).The application is titled, "A method… Read more

The market is being driven by a growing senior population, increased awareness of ALS, and an increasing incidence rate. The high cost of ALS therapy, on the other hand, may be an obstacle to the market throughout the projection period. North Read more

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) with the stream of 9.41% also noticed, India Oragenics, Inc. (AMEX:OGEN) encountered a rapid change of -2.47% in the last hour of Thursdays trading session. The post Striking Stock: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), Oragenics, Inc. (AMEX:OGEN) appeared first on Stocks Equity . Read more

Equities research analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report ($0.23) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Brainstorm Cell Therapeutics reported [] Read more

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) with the stream of -14.74% also noticed, India SentinelOne, Inc. (NYSE:S) encountered a rapid change of -1.46% in the last hour of Tuesdays trading session. The post Volume Movers: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), SentinelOne, Inc. (NYSE:S) appeared first on Stocks Equity . Read more

Millennium Management LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 371,460 shares of the biotechnology companys stock, valued at approximately $1,412,000. Millennium Management LLC owned 1.02% of Brainstorm Cell Therapeutics [] Read more

Equities analysts forecast that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will announce ($0.23) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Brainstorm Cell Therapeutics reported earnings [] Read more

Northern Trust Corp decreased its holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 83.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,761 shares of the biotechnology companys stock after selling 249,672 shares during the period. Northern Trust Corp owned 0.14% [] Read more

Charles Schwab Investment Management Inc. cut its holdings in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) by 85.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,287 shares of the biotechnology companys stock after selling 66,828 shares during the quarter. Charles Schwab Investment [] Read more

(RTTNews) - BrainStorm Cell Therapeutics Inc. (BCLI) reported new analyses from the phase 3 trial of NurOwn in amyotrophic lateral sclerosis. It showed that although the phase 3 trial did not reach statistical significance on the primary and secondary endpoints, pre-specified and post hoc analyses leveraging different methods of exploring the Read more

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Read more

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) shares, rose in value on Friday, 11/26/21, with the stock price up by 9.04% to the previous days close as strong demand from buyers drove the stock to $3.74. Actively observing the price movement in the last trading, the stock closed the session at $3.43, falling within a range of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Surged 9.04%, So What Now? Read More » Read more

The Gene and Cell Therapies Targeting CNS Disorders Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Gene Read more

Analysts forecast that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will announce ($0.23) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Brainstorm Cell Therapeutics earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.21). Brainstorm Cell Therapeutics posted earnings [] Read more